Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.
about
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Management of macroprolactinomas.Early prediction of long-term response to cabergoline in patients with macroprolactinomasPituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.Management of psychosis associated with a prolactinoma: case report and review of the literatureCabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?Medical therapy in acromegaly.Cabergoline-induced tricuspid regurgitation: Case report and review of literature.Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.The safety of treatments for prolactinomas.Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review.Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.Antioxidant Activity, Acetylcholinesterase, and Carbonic Anhydrase Inhibitory Properties of Novel Ureas Derived from Phenethylamines.A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.
P2860
Q33579615-1C7C4C8D-5168-4874-95B7-41CD9E3CAEB9Q33792371-1E4BB3A1-683F-4932-BD34-42932E4AC254Q34318860-13281656-3B6E-4CE2-B754-370A73A309D2Q35137687-F20E0366-7FFB-4BE2-BCD5-67F69E5DAAC0Q36888242-2A0E2F85-D207-450E-B0EB-E815BD3D2821Q37402278-0BF0B6F6-51E3-48EC-A343-83057624FA87Q37474118-FD1332F7-6DD8-434A-BE2F-CA4C208E03C2Q37656282-F0E8E939-F209-41B2-B61B-6788DFBAF845Q37859250-AE76B9DE-C084-46AF-ACE0-283544031A77Q37897988-A8A27B9B-A750-481B-9C4E-41EE9B205D10Q38112589-C75E1329-1F36-4A2C-801C-35A78033C9E4Q38435312-869C23DF-1F93-4EB5-8B5E-96D1F32CBBDCQ38726058-345C58FE-D84F-4597-A214-D9999EEAD394Q39317692-BA24EE8A-DF3C-48A9-A4F1-D7B0DE817097Q41473311-CEC54A2F-06F4-4EBF-B37F-AD1BBB403BB6Q42111747-61A66C23-267D-422B-A0E7-027F8AC0D61EQ47425359-F074E7A8-6403-414E-9D0C-F341166B9AE4Q50971056-F0D8C641-F9F6-4C32-B426-A1A331DB72F5Q51318710-238C1F65-EC3E-4B06-A006-02CA504D291CQ51425315-FFBCD5AC-8C91-49C5-9C8F-AF348FDD85B7
P2860
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@ast
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@en
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@nl
type
label
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@ast
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@en
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@nl
prefLabel
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@ast
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@en
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@nl
P2093
P356
P1476
Low dose cabergoline for hyper ...... ficant valvular heart disease.
@en
P2093
Alan S Rigby
Ammar Wakil
Andrew L Clark
Anna Kallvikbacka-Bennett
P356
10.1530/EJE-08-0365
P577
2008-07-14T00:00:00Z